Microbion Corporation

19 articles about Microbion Corporation

• Microbion Selected to Present at Advanced Wound Care Summit USA

  4/15/2024

  Microbion Corporation today announced that the company has been selected to present topical pravibismane for the treatment of diabetic foot infection (DFI) at the Advanced Wound Care Summit USA held at the Boston Marriot Long Wharf from April 16th to 17th.

• Microbion's Topical Pravibismane Phase 1b Moderate or Severe Diabetic Foot Ulcer Infection Study is Published in International Wound Journal

  4/4/2024

  Microbion Corporation today announced that the company has published results from its topical pravibismane Phase 1b study in the peer-reviewed International Wound Journal.

• Microbion's Pravibismane Granted Second FDA Orphan Drug Designation for the Treatment of Non-tuberculous Mycobacterial (NTM) Infections

  1/30/2024

  Microbion Corporation today announced that the company has been granted a second orphan drug designation for its lead drug candidate, pravibismane, for the treatment of non-tuberculous mycobacterial (NTM) infections.

• Microbion CEO to Participate in Panel Discussion at BioFuture 2023

  10/5/2023

  Microbion Corporation announced that Karim Lalji, CEO, will participate in a panel discussion during BioFuture 2023.

• Microbion Presented New Pravibismane Data Against Mycobacteroides abscessus at the 6th World Bronchiectasis and NTM Conference

  8/15/2023

  Microbion Corporation today announced that the company presented a poster highlighting the results from a series of in vitro and in vivo studies characterizing pravibismane's effect against Mycobacteroides abscessus at the recent 6th World Bronchiectasis & NTM Conference held in New York, NY.

• Microbion to Present Design of Ongoing Phase 2 Study Treating Diabetic Foot Ulcer Infections at the 2023 Military Health System Research Symposium

  8/14/2023

  Microbion Corporation today announced that the company will be presenting a poster that highlights key clinical study design elements from an ongoing phase 2 study assessing safety and efficacy of topical pravibismane in subjects suffering from moderate infections associated with chronic diabetic foot ulcers at the 2023 Military Health System Research Symposium being held from August 14th to 17th, 2023, at the Gaylord Palms Resort and Convention Center in Kissimmee, FL.

• Microbion Corp. Presents a Poster on Pravibismane's Activity Against Diabetic Foot Infection Patient Isolates

  5/10/2023

  Microbion Corporation announced that the company presented a poster focusing on pravibismane's activity against diabetic foot ulcer infection pathogens at the 9th International Symposium on the Diabetic Foot that is currently ongoing from May 10th to 13th, 2023 at The Hague, Netherlands.

• Microbion Corporation Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane Treatment of Diabetic Foot Infections

  3/9/2023

  Microbion Corporation today announced that a Phase 2, randomized, controlled study has been initiated to assess the safety and efficacy of topical pravibismane for the treatment of subjects with moderate infections of chronic diabetic foot ulcers (DFU).

• Microbion Corporation CEO to Present at the 2023 BIO CEO & Investor Conference

  2/3/2023

  Microbion Corporation, a clinical stage pharmaceutical company, announced that Karim Lalji, CEO of Microbion Pharma Corp., will be presenting at the 2023 BIO CEO & Investor Conference in New York, NY.

• Microbion Corporation Announces Poster Highlighting Pravibismane Activity Against Common Cystic Fibrosis Pulmonary Pathogens to be Presented at the North American Cystic Fibrosis Conference 2022

  11/3/2022

  Microbion Corporation today announced that the company will present a poster at the North American Cystic Fibrosis Conference, November 3 – 5, in Philadelphia, PA highlighting the activity of pravibismane against bacterial pathogens associated with lung infection in people with cystic fibrosis (CF).

• Microbion Corporation Announces Data Highlighting Pravibismane's Effect on Bacterial Energetics Presented at ASM Microbe 2022

  10/11/2022

  Microbion Corporation today announced that the company presented a poster highlighting the effect of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC.

• Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane

  10/4/2022

  Microbion Corporation announced that the US Patent and Trademark Office issued to Microbion, United States Patent No. 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane.

• Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical Pravibismane

  6/7/2022

  Funding will support exploratory phase 2 proof-of-concept study in patients hospitalized for moderate to severe diabetic foot ulcer infection (DFI).

• Microbion Corporation Announces Data Highlighting In Vitro Activity of Pravibismane in NTM, including Activity Against NTM Causing Intracellular Infections, to be Presented at the Colorado Mycobacteria Conference 2022

  6/1/2022

  Microbion Corporation announced that the company will present a poster highlighting the in vitro activity of pravibismane against M. avium and M. abscessus non-tuberculous mycobacteria at the Colorado Mycobacteria Conference 2022: Focus on NTM conference taking place from May 31 to June 3, 2022, at Colorado State University.

• Microbion Corporation Appoints Robert A. Gillam as Chairman of Microbion's Board of Directors

  7/29/2021

  Microbion Corporation of Bozeman, MT, announced that Mr. Robert A. Gillam, CFA, will be joining Microbion's Board of Directors as Chairman, replacing Mr. Karim Lalji in the Board Chairman role effective immediately.

• Microbion Awarded up to $17.1 Million from CARB-X and the Cystic Fibrosis Foundation to Develop Inhaled Antimicrobial for Chronic Respiratory Infections in CF

  5/28/2020

  Potential first in a new class of antimicrobial drugs shown to have potent activity against CF-related pathogens in the lab

• Microbion Corporation Announces Orphan Drug Designation Granted for Pravibismane Suspension for Inhalation by US FDA

  5/27/2020

  Orphan drug designation granted for treatment (management) of pulmonary infections in patients with cystic fibrosis

• Microbion Corporation to Present Data Highlighting Broad Spectrum Activity of BisEDT at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

  4/15/2019

  BisEDT is the active pharmaceutical ingredient of Microbion's therapeutic formulation MBN-101.

• China's Hasico Secures China Rights To Microbion Corporation's Chronic Wound Treatment

  3/11/2016